2021–2022[]
|
SVG NEEDED |
Ukoniq was approved under the United States Food and Drug Administration's accelerated approval program in 2021, and would be put on sale the same year. In April 2022, the drug was withdrawn from markets due to concerns after a decrease in overall survival in clinical trials compared to the control group was noted.